Articles tagged with Ovarian Cancer
Philanthropists Foster and Lynn Friess are tripling-match donations up to $100,000 for TGen's unTEAL a cure event. The total raised will support groundbreaking research on ovarian cancer cases.
A new study published in Journal of Clinical Oncology found that adding targeted therapy bevacizumab to treatment for advanced ovarian cancer patients is not cost-effective. The researchers analyzed a clinical trial and found that the additional survival benefit was offset by high costs.
Researchers at York University have identified a key role for microRNA 376c in allowing ovarian cancer cells to thrive despite chemotherapy. By targeting the receptor ALK7, this microRNA enables cancer cells to survive and resist cell death.
Research using primary care records reveals that GPs often take more than a month to record an ovarian cancer diagnosis after receiving notification from specialists. In fact, one in ten cases took over four weeks, while 11% of records showed incorrect or premature diagnoses.
Scientists at Georgia Institute of Technology have found a regulatory RNA called miR-429 that can induce metastatic cancer cells to convert back into less invasive forms. This discovery may allow physicians to treat ovarian cancer more effectively with traditional chemotherapy.
African American women have lower incidence rates yet poorer survival rates for ovarian cancer compared to women of other races. The study aims to determine how risk factors differ between African American and white women, with the goal of preventing this deadly disease.
Researchers at Georgia Tech have developed a new treatment system that uses magnetic nanoparticles to capture free-floating cancer cells, slowing tumor progression in humans. The system aims to reduce chemotherapy side effects by removing the primary source of metastasis.
Survival rates for breast, ovarian, colorectal, and lung cancer are higher in Australia, Canada, and Sweden compared to the UK and Denmark. International differences narrowed for breast cancer, but significant disparities remain in other cancers.
Preethi Gunaratne's research aims to unleash the body's natural cancer-fighting agents using microRNAs, which have been shown to suppress the growth of cancer cells. Gold nanoparticles are being explored as a potential carrier for these molecules, offering a promising treatment for ovarian cancer with minimal side effects.
Researchers at the University of Gothenburg have confirmed that ovarian cancer tissue and healthy tissue smell different, using an electronic nose. The discovery has major practical implications for early detection and treatment of ovarian cancer.
Scientists have identified age-related gene-specific accumulation of DNA methylation that suppresses the critical TGF-beta pathway contributing to ovarian carcinogenesis. This finding provides crucial information for future translational research and may lead to targeted therapeutic interventions.
Researchers at Duke University Medical Center found evidence of epigenetics in ovarian cancer, specifically DNA methylation affecting the TGF-beta signaling pathway. This deregulation contributes to tumor growth and metastasis, highlighting a potential target for epigenetic therapies.
Researchers found that ovarian cancer screening can only slightly reduce mortality rates, highlighting the need for prevention and better treatments. For high-risk women, targeted screening may offer more hope in reducing deaths from ovarian cancer.
Incorporating ovarian cancer subtypes into screening models reduces predicted mortality rates. However, catching slower-growing cancers won't significantly impact deaths compared to more lethal tumors.
AnaLisa DiFeo will investigate microRNA profiles and their association with chemotherapy sensitivity in ovarian cancer tumors. Her research aims to identify new drug targets for overcoming chemoresistance and improving treatment outcomes.
A new study aims to discover the genetic and molecular underpinnings of small cell carcinoma of the ovary (SCCO), a rare and aggressive cancer affecting young women. Researchers will collect tumor and blood samples using advanced genomic approaches to understand the disease's origins and develop effective treatments.
In a Phase I trial, MK-4827 demonstrated anti-tumour responses in both sporadic and BRCA1/2 mutation-associated cancers. Patients with exhausted standard therapies showed significant shrinkage or stabilization of tumours for extended periods.
Using OncoMap, researchers can identify specific mutations in oncogenes that drive ovarian cancer growth and choose targeted drugs to halt tumor progression. The technique holds promise for personalized medicine in treating advanced ovarian cancer.
Researchers at the Centenary Institute discovered a new death pathway that can break drug resistance in ovarian cancer. The treatment, FTY720, kills ovarian cancer cells through necrosis, making it resistant to relapse. Further clinical trials are needed to confirm its effectiveness.
A study analyzing European Prospective Investigation into Cancer and Nutrition data found that current hormone therapy use increases the risk of ovarian cancer by 29%. The risk did not differ by type or duration of hormone therapy, suggesting a potential long-term hazard.
A study found that a peptide being tested to treat atherosclerosis significantly inhibited the growth of ovarian cancer in human cell lines and mouse models. The peptide, an apoA-I mimetic, was shown to be effective when administered via injection or ingestion, with minimal side effects.
Dr Clare Scott's VCA fellowship aims to uncover the origins of ovarian cancer and develop new laboratory models for studying human cancers. The funding will also support the use of a web portal, CART-WHEEL.org, to coordinate patient information and research studies.
The Program in Women's Oncology at Women & Infants Hospital will receive a $5,000 donation from Pink Heals Rhode Island to support the Patient Advocate Program. The program helps eliminate obstacles and stresses for women battling breast cancer by arranging transportation, financial assistance, and other services.
Women who inherit BRCA1 or BRCA2 gene mutations from their father are at increased risk of breast and ovarian cancer, yet this risk is often overlooked. A study found that patients with a paternal family history of cancer were 5 times more likely to be referred for genetic testing than those with a maternal family history.
A new study found that estrogen replacement therapy significantly speeds up ovarian cancer growth and increases the likelihood of cancer metastasizing to the lymph nodes. Researchers discovered estrogen-regulated genes specific to ER+ ovarian cancer that can be targeted with new anti-estrogen therapies.
A renowned gynecologic oncologist expresses concerns about a major ovarian cancer study, highlighting the need for targeted genetics-based treatments over delayed treatment timing. The study found no significant difference in survival rates between early and delayed chemotherapy groups.
A randomized study found that adding topotecan to carboplatin and paclitaxel did not improve progression-free survival in patients with ovarian cancer, but increased toxicity. The standard regimen of carboplatin and paclitaxel remains the best care for epithelial ovarian cancer.
A Phase II clinical trial of MLN8237, a selective Aurora A kinase inhibitor, demonstrates single-agent activity with durable disease control in some patients with ovarian cancer resistant to platinum-based chemotherapy. The study found encouraging responses in several patients, suggesting potential for future combination therapies.
A molecular imaging technique may help identify early response to treatment in cisplatin-resistant ovarian cancer, potentially reducing unnecessary side effects and offering more effective treatments. Researchers used a PET probe to monitor tumor growth in mice with human ovarian cancer.
A new randomised trial shows that starting chemotherapy earlier does not improve survival or quality of life for women with relapsed ovarian cancer. The study found that patients who received early treatment experienced a faster deterioration in quality of life, including role, emotional, social, and fatigue symptoms.
Research published in Annals of Oncology suggests that intrauterine devices releasing progestin hormone levonorgestrel combined with GnRH injections can halt and reverse cancer growth in women aged 40 or younger. The treatment has shown promise in treating specific types of endometrial cancer, preserving fertility for young women.
Two studies found new genetic variants linked to ovarian cancer risk in the general population, particularly in women with serous ovarian cancer. The variants were more common in women with aggressive disease and may be used for closer surveillance and preventive approaches.
A consortium of cancer researchers has identified four chromosome locations with genetic changes that may alter a woman's risk of developing ovarian cancer. These findings are based on a large genome-wide association study and could lead to individualized risk assessments for ovarian cancer.
Researchers have identified two genes, ARID1A and PPP2R1A, whose mutations are linked to ovarian clear cell carcinoma, a highly aggressive form of ovarian cancer. The study found that ARID1A mutations were present in over half of the tumors studied, suggesting a significant role in this type of cancer.
A long-term study found that women with BRCA1 and BRCA2 genetic mutations significantly reduced their risk of breast and ovarian cancer with preventive surgeries. Risk-reducing mastectomies and removal of the fallopian tubes and ovaries lowered cancer risks, including those with prior breast cancer.
Prophylactic mastectomy and salpingo-oophorectomy significantly reduce breast and ovarian cancer risks in women with BRCA1/2 mutations. The study found that risk-reducing mastectomy decreased breast cancer risk, while salpingo-oophorectomy lowered ovarian cancer risk.
Women with a family history of breast or ovarian cancer can benefit from prophylactic surgeries to remove ovaries, fallopian tubes, or breasts, increasing survival rates and eliminating risk. Genetic testing is crucial for identifying the BRCA1 and BRCA2 genes, which significantly increase cancer risk.
The study found that depleting SIK2 from ovarian cancers sensitized the cells to paclitaxel, making it more effective in stopping cancer growth. Levels of SIK2 protein are increased in approximately 30 percent of ovarian cancers and associated with poorer survival rates.
Researchers have discovered a protein called Salt Inducible Kinase 2 (SIK2) that plays a key role in regulating cell division and may be an attractive target for treating ovarian cancer. Combination therapies targeting different phases of the cell cycle are highly desirable for optimal cancer treatment.
Researchers found that EZH2 promotes tumor growth by shutting down genes that block formation of new blood vessels. Silencing EZH2 in ovarian cancer tumors reduced average tumor weight by 62% and increased programmed death of tumor cells.
Despite advancements in cancer biomarker research, many initial breakthroughs fail to translate to clinical success due to issues with study design and interpretation. Seven biomarkers initially hailed as promising have been reevaluated, highlighting problems with pre-analytical, analytical, and post-analytical study design.
A recent study suggests that a new drug, Olaparib, can reduce tumor size in women with advanced hereditary ovarian and breast cancers, offering a promising targeted therapy approach. The Phase II trials showed significant shrinkage in tumor size and relatively mild toxicities.
The new test uses mass spectrometry to analyze metabolites in a single drop of blood serum, accurately identifying women with ovarian cancer in all tested patients. Further testing will be conducted on 500 patients to confirm the results and explore its potential for detecting other types of cancers.
Researchers at Yale University have discovered a genetic marker that can help predict ovarian cancer risk. The KRAS-variant was found in 25% of all ovarian cancer patients and 61% of those with a family history of breast and ovarian cancer, suggesting it may be a new marker for high-risk families.
A new study reveals that shorter leukocyte telomere length is associated with a significantly increased risk of developing cancer and dying from cancer. Participants with the shortest telomere lengths had approximately three times the risk of cancer compared to those in the longest group.
Researchers at TGen have found a way to revive chemotherapy in ovarian cancer patients who no longer respond to conventional treatment. By inhibiting the CHEK1 protein, they were able to make these cells sensitive again to cisplatin, a widely used platinum-based chemotherapy drug.
Two phase-2 trials demonstrate the efficacy of olaparib in treating advanced ovarian and breast cancer in patients with BRCA1 or BRCA2 mutations. The higher dose of olaparib showed better treatment response rates compared to the lower dose, with ORR of 33% and 41% respectively.
Researchers at Arizona State University and Fred Hutchinson Cancer Research Center develop a new method to identify biomarkers for ovarian cancer using antibodies. They found 19 distinct scFvs that selectively bound to proteins exclusively found in ovarian cancerous blood serum, providing potential for significant improvements in patie...
A phase I clinical trial of the combination of decitabine and carboplatin has shown promising results in treating late-stage ovarian cancer, with four patients experiencing no disease progression after six months. The treatment regimen has been found to be well-tolerated, with mild adverse reactions.
A new treatment regimen combining bevacizumab with standard chemotherapy significantly extends progression-free survival for women with advanced ovarian cancer, reducing disease worsening to 14.1 months compared to 10.3 months. The trial results also point to the possibility of more personalized and effective treatment in the future.
Researchers found that CA-125 change over time can detect invasive, high-grade ovarian cancers at curable stages in post-menopausal women. The study identified a promising first step towards screening, but acknowledges the need for further research and a large-scale randomized trial to confirm the findings.
Researchers found that flaxseed-enriched diets decreased late-stage ovarian tumor severity and increased survival rates in hens. The study also showed improved weight control and reduced metastatic spread in hens fed the flaxseed diet, suggesting potential benefits for human ovarian cancer treatment.
Researchers found that curcumin nanoparticles, delivered via nanoparticles, increased the sensitivity of resistant ovarian cancer cells to chemotherapy and radiation. The treatment enables lower doses of cisplatin and radiation, improving therapeutic outcomes without increasing toxicity.
Fox Chase researchers have discovered that early ovarian cancers arise in inclusion cysts of the ovary. The team found gene expression patterns and extra chromosomes in cells from these cysts compared to normal surface epithelium cells.
Researchers have found that patients with hereditary ovarian cancer are more likely to experience secondary tumours in their liver and spleen, despite better overall prognosis. A new approach suggests testing these patients for BRCA1 and BRCA2 genes to ensure tailored treatment.
Researchers have identified a new breast and ovarian cancer susceptibility gene, RAD51C, in a German study. The gene is associated with a high risk of breast and ovarian cancer, particularly in familial cases.
The Anne Rita Monahan Foundation has raised $50,000 for ovarian cancer research at the Translational Genomics Research Institute (TGen). Funds from the 2nd annual Tea for TEAL event will support the development of a reliable screening test and precision therapy for ovarian cancer.
Researchers at Fox Chase Cancer Center have isolated an engineered antibody, GS45, that targets the Müllerian Inhibiting Substance Type II Receptor on ovarian cancer cells. This unique target is scarce in normal tissue, reducing the risk of side effects associated with traditional targeted therapies.
Researchers found that stress-activated protein protects fugitive ovarian cancer cells from programmed death, allowing them to escape the primary tumor and metastasize. The study suggests that restoring cancer cells' vulnerability to anoikis could suppress tumor growth and metastasis.
Researchers find that stress hormones can protect ovarian cancer cells from anoikis, promoting tumor growth. Higher levels of activated FAK are linked to accelerated mortality in ovarian cancer patients.